Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Sep 19, 2025

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Genetic Subtype-Based International Prognostic Index Prognostic Model in Diffuse Large B-Cell Lymphoma.

Lan Mi¹, Jili Deng², Jiayue Qin³

¹Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) Department of Lymphoma Peking University Cancer Hospital & Institute Beijing China.

|June 18, 2025

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Genetic and Clinical Features in TP53-Mutated Patients With Myelodysplastic Neoplasms: A Retrospective Study Based on Next-Generation Sequencing Data.

Cancer reports (Hoboken, N.J.)·2026

Same author

Mutation Profiling, Efficacy Monitoring, and Prognosis Evaluation Using Circulating Tumor DNA in Peripheral T-Cell Lymphoma: A Prospective, Multicenter, Observational Study.

American journal of hematology·2026

Same author

Association of CYP2C19 Single Nucleotide Polymorphism With Hemorrhagic Cystitis After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation.

Clinical transplantation·2026

Same author

Prognostic value of CEBPA bZIP signatures in cytogenetically normal acute myeloid leukaemia.

British journal of haematology·2025

Same author

Stable Expressed <i>DNMT3A</i> Mutants Predict a Poor Prognosis in Acute Myeloid Leukemia Patients Without Receiving Hematopoietic Stem Cell Transplantation.

MedComm·2025

Same author

Acute Myeloid Leukemia with Normal Cytogenetics and <i>NPM1</i>-Mutation: Impact of Mutation Topography on Outcomes.

Biomedicines·2025

Same journal

Epilepsy: Epidemiology, Molecular Pathogenesis, and Clinical Management.

MedComm·2026

Same journal

Metabolic Dysfunction-Associated Fatty Liver Disease: From Pathogenesis to Treatment.

MedComm·2026

Same journal

Dexmedetomidine Rapidly Relieves Stress-Induced Hyperalgesia via Presynaptic <i>α</i>2-Adrenergic Inhibition at Orbitofrontal-Insular Glutamatergic Synapses.

MedComm·2026

Same journal

Osteoarthritis: Epidemiology, Diagnosis, and Treatment.

MedComm·2026

Same journal

Multiomics Identification and Validation of an Integrin-Extracellular Matrix Network Driving Respiratory Syncytial Virus-Induced Lung Injury and Repair.

MedComm·2026

Same journal

A Low Serum Calcium-to-Potassium Ratio Predicts Postpartum Venous Thromboembolism Risk: Mediation by Hemoglobin and D-Dimer in a Multicenter Cohort.

MedComm·2026

See all related articles

This summary is machine-generated.

A new integrated prognostic model for diffuse large B-cell lymphoma (DLBCL) combines molecular subtypes and clinical factors. This model improves survival prediction accuracy compared to existing methods, aiding treatment decisions.

Area of Science:

Hematology
Oncology
Genomics

Background:

Molecular subtyping aids drug selection in diffuse large B-cell lymphoma (DLBCL).
An integrated prognostic model combining molecular and clinical features for DLBCL is lacking.

Purpose of the Study:

To develop and validate an integrated prognostic model for DLBCL.
To improve prognostic accuracy and guide clinical treatment decisions.

Main Methods:

Retrospective analysis of whole genome sequencing, whole exome sequencing, and FISH in DLBCL patients.
Development of a simplified LymphType algorithm.
Integration of molecular subtypes and International Prognostic Index (IPI) into a novel prognostic model.
Validation in an in-house cohort (N=100) and three public cohorts (N=1480).

Keywords:

International Prognostic Index LymphType defined genetic subtype diffuse large B‐cell lymphoma integrated prognostic model

More Related Videos

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Related Experiment Videos

Last Updated: Sep 19, 2025

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Main Results:

The integrated model demonstrated superior discrimination of overall survival (concordance index 0.773) compared to IPI (0.724) and classification algorithm alone (0.648).
A four-category risk model (low, low-intermediate, high-intermediate, high) showed significant prognostic separation across all endpoints (p < 0.001).
The model was validated in both in-house and public cohorts.

Conclusions:

The proposed integrated prognostic stratification system offers accurate prognosis assessment for DLBCL.
This system provides a foundation for personalized follow-up treatment strategies in DLBCL patients.